(IMVT) – Hot Comments
-
Guggenheim reiterates Buy rating on Tourmaline Bio (TRML), "news is likely to increase investors' perceived risk"
-
Immunovant (IMVT) PT Raised to $52 at Stifel
-
-
-
-
-
-
-
-
-
-
Back to IMVT Stock Lookup